$NHC
NATIONAL HEALTHCARE CORP

2017 Q1 Form 10-Q Financial Statement

#000104733517000112 Filed on May 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $238.5M $229.6M
YoY Change 3.9% 3.23%
Cost Of Revenue $138.1M $130.0M
YoY Change 6.23% 3.42%
Gross Profit $100.5M $99.60M
YoY Change 0.9% 3.0%
Gross Profit Margin 42.13% 43.38%
Selling, General & Admin $10.10M $10.30M
YoY Change -1.94% 3.0%
% of Gross Profit 10.05% 10.34%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $10.30M $9.354M
YoY Change 10.06% 4.71%
% of Gross Profit 10.24% 9.39%
Operating Expenses $83.50M $81.00M
YoY Change 3.09% 2.92%
Operating Profit $15.86M $17.62M
YoY Change -9.99% 1.08%
Interest Expense $1.058M $954.0K
YoY Change 10.9% 61.69%
% of Operating Profit 6.67% 5.41%
Other Income/Expense, Net $4.768M $4.773M
YoY Change -0.1% 13.05%
Pretax Income $20.63M $22.40M
YoY Change -7.88% 3.41%
Income Tax $7.999M $8.698M
% Of Pretax Income 38.77% 38.84%
Net Earnings $12.73M $13.70M
YoY Change -7.09% 3.45%
Net Earnings / Revenue 5.34% 5.97%
Basic Earnings Per Share $0.84 $0.92
Diluted Earnings Per Share $0.84 $0.91
COMMON SHARES
Basic Shares Outstanding 15.17M 14.92M
Diluted Shares Outstanding 15.21M 15.14M

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $183.4M $175.1M
YoY Change 4.74% -17.79%
Cash & Equivalents $47.10M $49.18M
Short-Term Investments $136.3M $125.9M
Other Short-Term Assets $29.50M $30.50M
YoY Change -3.28% 1.67%
Inventory $7.320M $7.298M
Prepaid Expenses
Receivables $83.34M $81.73M
Other Receivables $900.0K $1.700M
Total Short-Term Assets $304.5M $296.3M
YoY Change 2.76% -10.79%
LONG-TERM ASSETS
Property, Plant & Equipment $557.4M $540.1M
YoY Change 3.2% 4.19%
Goodwill $17.60M $17.60M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $36.40M $37.20M
YoY Change -2.15% 4.49%
Other Assets $217.1M $231.7M
YoY Change -6.27% 31.85%
Total Long-Term Assets $774.5M $771.8M
YoY Change 0.36% 1.58%
TOTAL ASSETS
Total Short-Term Assets $304.5M $296.3M
Total Long-Term Assets $774.5M $771.8M
Total Assets $1.079B $1.068B
YoY Change 1.02% -2.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.60M $17.90M
YoY Change 3.91% -13.53%
Accrued Expenses $67.50M $78.10M
YoY Change -13.57% 7.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.500M $3.300M
YoY Change 6.06% 6.45%
Total Short-Term Liabilities $132.1M $138.8M
YoY Change -4.86% -23.06%
LONG-TERM LIABILITIES
Long-Term Debt $120.0M $120.0M
YoY Change 0.0% 181.03%
Other Long-Term Liabilities $16.83M $16.79M
YoY Change 0.25% -86.04%
Total Long-Term Liabilities $136.8M $136.8M
YoY Change 0.03% -16.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $132.1M $138.8M
Total Long-Term Liabilities $136.8M $136.8M
Total Liabilities $402.3M $275.6M
YoY Change 45.96% -19.77%
SHAREHOLDERS EQUITY
Retained Earnings $397.8M $375.6M
YoY Change 5.92%
Common Stock $152.0K $153.0K
YoY Change -0.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $675.9M $654.6M
YoY Change
Total Liabilities & Shareholders Equity $1.079B $1.068B
YoY Change 1.02% -2.18%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income $12.73M $13.70M
YoY Change -7.09% 3.45%
Depreciation, Depletion And Amortization $10.30M $9.354M
YoY Change 10.06% 4.71%
Cash From Operating Activities $13.01M $17.73M
YoY Change -26.62% -27.28%
INVESTING ACTIVITIES
Capital Expenditures $8.066M $13.43M
YoY Change -39.95% 6.77%
Acquisitions
YoY Change
Other Investing Activities $34.30M $1.800M
YoY Change 1805.56% -238.46%
Cash From Investing Activities $26.27M -$8.439M
YoY Change -411.32% -39.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$817.0K $9.330M
YoY Change -108.76% 85.27%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -7.063M 1.683M
YoY Change -519.67% -180.95%
NET CHANGE
Cash From Operating Activities 13.01M 17.73M
Cash From Investing Activities 26.27M -8.439M
Cash From Financing Activities -7.063M 1.683M
Net Change In Cash 32.22M 10.98M
YoY Change 193.58% 29.97%
FREE CASH FLOW
Cash From Operating Activities $13.01M $17.73M
Capital Expenditures $8.066M $13.43M
Free Cash Flow $4.945M $4.299M
YoY Change 15.03% -63.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Self Insurance Reserve
SelfInsuranceReserve
91162000
CY2016 nhc Annual Excess Coverage
AnnualExcessCoverage
9000000
CY2017Q1 nhc Annual Excess Coverage
AnnualExcessCoverage
9000000
CY2017Q1 nhc Direct Business Coverage Statutory Limits
DirectBusinessCoverageStatutoryLimits
1000000
CY2017Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
83339000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
82531000
CY2017Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
18579000
CY2016Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
18593000
CY2017Q1 nhc Dividends And Other Net Realized Gains And Losses On Sales Of Securities
DividendsAndOtherNetRealizedGainsAndLossesOnSalesOfSecurities
1724000
CY2016Q1 nhc Dividends And Other Net Realized Gains And Losses On Sales Of Securities
DividendsAndOtherNetRealizedGainsAndLossesOnSalesOfSecurities
1861000
CY2017Q1 nhc Income Tax Rate Reconciliation Exercise Of Stock Options Amount
IncomeTaxRateReconciliationExerciseOfStockOptionsAmount
124000
CY2017Q1 nhc Increase Decrease In Due To Third Party Payors
IncreaseDecreaseInDueToThirdPartyPayors
668000
CY2016Q1 nhc Increase Decrease In Due To Third Party Payors
IncreaseDecreaseInDueToThirdPartyPayors
944000
CY2017Q1 nhc Noncontrolling Interest Increase From Capital Contribution
NoncontrollingInterestIncreaseFromCapitalContribution
970000
CY2017Q1 nhc Number Of Assisted Living Facilities
NumberOfAssistedLivingFacilities
24
CY2017Q1 nhc Number Of Beds
NumberOfBeds
9597
CY2017Q1 nhc Number Of Homecare Programs
NumberOfHomecarePrograms
36
CY2017Q1 nhc Number Of Independent Living Facilities
NumberOfIndependentLivingFacilities
5
CY2017Q1 nhc Number Of Skilled Nursing Centers
NumberOfSkilledNursingCenters
76
CY2017Q1 nhc Proceeds Payments Tax Benefit Expense From Stockbased Compensation
ProceedsPaymentsTaxBenefitExpenseFromStockbasedCompensation
CY2016Q1 nhc Proceeds Payments Tax Benefit Expense From Stockbased Compensation
ProceedsPaymentsTaxBenefitExpenseFromStockbasedCompensation
-1186000
CY2017Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
17687000
CY2016Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
17019000
CY2017Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
41976000
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
65912000
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
383777000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
373516000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
65501000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
66068000
CY2017Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
212366000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
211457000
CY2016Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
-1186000
CY2016Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
286000
CY2017Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
92000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
92000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
286000
CY2017Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6663000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
5743000
CY2017Q1 us-gaap Assets
Assets
1078976000
CY2016Q4 us-gaap Assets
Assets
1087447000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
304450000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
290857000
CY2017Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
154408000
CY2016Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
185968000
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
289180000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
321717000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
107010000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
108730000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2414000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3157000
CY2017Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
184584000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
216144000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
74319000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
91211000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
72872000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
89269000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
66671000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
79827000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
66517000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
79502000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
749000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
717000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
13418000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
14181000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
13450000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
14216000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
152839000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
183704000
CY2017Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3533000
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3481000
CY2017Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
25845000
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
26748000
CY2017Q1 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
35967000
CY2017Q1 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
5200000
CY2017Q1 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
5200000
CY2017Q1 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
5200000
CY2017Q1 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
5200000
CY2017Q1 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
5200000
CY2017Q1 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
9967000
CY2017Q1 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
6589000
CY2017Q1 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
29378000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47096000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49183000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26335000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31589000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49314000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63809000
CY2016Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63638000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
32220000
CY2016Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
14324000
CY2017Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.45
CY2016Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.40
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15179930
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15162938
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15179930
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15162938
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
152000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
152000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
12161000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
21257000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-95000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
CY2017Q1 us-gaap Continuing Care Retirement Communities Advance Fees Obligation For Future Services Amount
ContinuingCareRetirementCommunitiesAdvanceFeesObligationForFutureServicesAmount
3236000
CY2016Q4 us-gaap Continuing Care Retirement Communities Advance Fees Obligation For Future Services Amount
ContinuingCareRetirementCommunitiesAdvanceFeesObligationForFutureServicesAmount
3236000
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
223379000
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
211964000
CY2017Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5594000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3362000
CY2017Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
20007000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
22072000
CY2017Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
5909000
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
5244000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
10295000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9354000
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10295000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9354000
CY2016Q1 us-gaap Dividends Common Stock
DividendsCommonStock
6105000
CY2017Q1 us-gaap Dividends Common Stock
DividendsCommonStock
6831000
CY2017Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
6831000
CY2016Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
6818000
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.92
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.84
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.91
CY2017Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.388
CY2016Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.388
CY2016Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
4665000
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8382000
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P5Y
CY2017Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
2609000
CY2016Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
2851000
CY2017Q1 us-gaap Gain Loss On Sale Of Securities Net
GainLossOnSaleOfSecuritiesNet
34000
CY2016Q1 us-gaap Gain Loss On Sale Of Securities Net
GainLossOnSaleOfSecuritiesNet
279000
CY2017Q1 us-gaap Goodwill
Goodwill
17600000
CY2016Q4 us-gaap Goodwill
Goodwill
17600000
CY2017Q1 us-gaap Health Care Organization Other Revenue
HealthCareOrganizationOtherRevenue
11284000
CY2016Q1 us-gaap Health Care Organization Other Revenue
HealthCareOrganizationOtherRevenue
11482000
CY2017Q1 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
227959000
CY2016Q1 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
218106000
CY2017Q1 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
239243000
CY2016Q1 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
229588000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
20632000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
22397000
CY2017Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1526000
CY2016Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1505000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7999000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8698000
CY2017Q1 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
49000
CY2016Q1 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
86000
CY2017Q1 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
175000
CY2016Q1 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
175000
CY2017Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
CY2017Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-14000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2237000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2691000
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-478000
CY2017Q1 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-23936000
CY2016Q1 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-14624000
CY2017Q1 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-519000
CY2016Q1 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
206000
CY2017Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1657000
CY2016Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-1477000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2232000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2158000
CY2017Q1 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-662000
CY2016Q1 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
129000
CY2017Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-4665000
CY2016Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-3203000
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-188000
CY2016Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-270000
CY2017Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
8356000
CY2016Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
6749000
CY2017Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
528000
CY2016Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
494000
CY2017Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1280000
CY2016Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
953000
CY2017Q1 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
CY2016Q1 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
194275
CY2017Q1 us-gaap Interest Expense
InterestExpense
1058000
CY2016Q1 us-gaap Interest Expense
InterestExpense
954000
CY2017Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1518000
CY2016Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1407000
CY2017Q1 us-gaap Inventory Net
InventoryNet
7320000
CY2016Q4 us-gaap Inventory Net
InventoryNet
7508000
CY2017Q1 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
36351000
CY2016Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
37242000
CY2017Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
138055000
CY2016Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
130020000
CY2017Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
10088000
CY2016Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
10327000
CY2017Q1 us-gaap Liabilities
Liabilities
402251000
CY2016Q4 us-gaap Liabilities
Liabilities
417836000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1078976000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
34200000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
168200000
CY2017Q1 us-gaap Long Term Debt
LongTermDebt
120000000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1087447000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
132062000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
150928000
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
120000000
CY2017Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
120000000
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
120000000
CY2017Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
136341000
CY2016Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
138013000
CY2017Q1 us-gaap Marketable Securities Restricted Current
MarketableSecuritiesRestrictedCurrent
10979000
CY2016Q4 us-gaap Marketable Securities Restricted Current
MarketableSecuritiesRestrictedCurrent
22773000
CY2017Q1 us-gaap Marketable Securities Restricted Noncurrent
MarketableSecuritiesRestrictedNoncurrent
141860000
CY2016Q4 us-gaap Marketable Securities Restricted Noncurrent
MarketableSecuritiesRestrictedNoncurrent
160931000
CY2017Q1 us-gaap Minority Interest
MinorityInterest
875000
CY2016Q4 us-gaap Minority Interest
MinorityInterest
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-7063000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1683000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
26272000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-11609000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
13011000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
24250000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
12728000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
13699000
CY2017Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-95000
CY2016Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
CY2017Q1 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
875000
CY2016Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
3259000
CY2017Q1 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
13270000
CY2016Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
13820000
CY2017Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2017Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2017Q1 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
10
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
15864000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
17624000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
339200000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
34200000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
34200000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
34200000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
34200000
CY2017Q1 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
9405000
CY2016Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
9924000
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
217131000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
236966000
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7558000
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-567000
CY2017Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
34000
CY2016Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
279000
CY2017Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-408000
CY2016Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
4667000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-941000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
12504000
CY2017Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
63883000
CY2016Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
61309000
CY2017Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
17905000
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13207000
CY2017Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
16830000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
16302000
CY2017Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4768000
CY2016Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4773000
CY2017Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
11284000
CY2016Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
11482000
CY2017Q1 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2016 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2017Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
6818000
CY2016Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
5995000
CY2017Q1 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
176000
CY2016Q1 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
904000
CY2017Q1 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
CY2016Q1 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
1844000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8066000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13432000
CY2017Q1 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
2291000
CY2016Q1 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
11079000
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3928000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2648000
CY2017Q1 us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
2918000
CY2016Q1 us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
77000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
817000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9330000
CY2017Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
970000
CY2016Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
33887000
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
15573000
CY2017Q1 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
33887000
CY2016Q1 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
15573000
CY2017Q1 us-gaap Profit Loss
ProfitLoss
12633000
CY2016Q1 us-gaap Profit Loss
ProfitLoss
13699000
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
941172000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
933140000
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
557395000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
559624000
CY2017Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1883000
CY2016Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1885000
CY2017Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
34000
CY2016Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
279000
CY2017Q1 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
851000
CY2016Q1 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
801000
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
16713000
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
14455000
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
14572000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
3125000
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2141000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2129000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
397831000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
391934000
CY2017Q1 us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">D</div><div style="display: inline; font-style: italic;">eferred Revenue </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"></div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Deferred revenue includes the deferred gain on the sale of assets to National Health Corporation (&#x201c;National&#x201d;)</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">,</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> the non-refundable portion</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10%)</div> of CCRC entrance fees being amortized over the remaining life expectancies of the residents, and premiums received within our workers&#x2019; compensation and professional liability companies that are not yet earned. </div></div></div></div></div></div></div></div></div></div></div></div>
CY2017Q1 us-gaap Self Insurance Reserve
SelfInsuranceReserve
94823000
CY2017Q1 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
25551000
CY2016Q4 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
25898000
CY2017Q1 us-gaap Self Insurance Reserve Noncurrent
SelfInsuranceReserveNoncurrent
69272000
CY2016Q4 us-gaap Self Insurance Reserve Noncurrent
SelfInsuranceReserveNoncurrent
65264000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
92000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
286000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0311
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0309
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.166
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.158
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0211
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0089
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
160967
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
56.26
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
656
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
46.69
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
56291
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1072425
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2421000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
621390
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
177959
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1233392
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.15
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
55.48
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
70.78
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
47.16
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
48.08
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
62.54
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
72.96
CY2017Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1233392
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y73D
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2421000
CY2017Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
70.78
CY2017Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y219D
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
499066
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
16992
CY2016Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9330000
CY2017Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
817000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
675850000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
669611000
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
630996000
CY2016Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
654578000
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
669611000
CY2017Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
676725000
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Estimates and Assumptions</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and could cause our reported net income to vary significantly from period to period.</div></div></div></div></div></div></div></div></div></div></div></div>
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15212133
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15135446
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15173491
CY2016Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14916905

Files In Submission

Name View Source Status
0001047335-17-000112-index-headers.html Edgar Link pending
0001047335-17-000112-index.html Edgar Link pending
0001047335-17-000112.txt Edgar Link pending
0001047335-17-000112-xbrl.zip Edgar Link pending
exhibit311flatt.htm Edgar Link pending
exhibit312kidd.htm Edgar Link pending
exhibit32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nhc-20170331.xml Edgar Link completed
nhc-20170331.xsd Edgar Link pending
nhc-20170331_cal.xml Edgar Link unprocessable
nhc-20170331_def.xml Edgar Link unprocessable
nhc-20170331_lab.xml Edgar Link unprocessable
nhc-20170331_pre.xml Edgar Link unprocessable
nhcmarch2017form10q.htm Edgar Link pending
nhcmarch2017form10q001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending